Miriam
Redrado Jordán
Clínica Universitaria de Navarra
Pamplona, EspañaPublikationen in Zusammenarbeit mit Forschern von Clínica Universitaria de Navarra (4)
2021
-
Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy
Cancers, Vol. 13, Núm. 11
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2019
-
Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients
Journal of Clinical Medicine, Vol. 8, Núm. 12
2011
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142